6535.TWO
Price:
$148.5
Market Cap:
$24.73B
Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops therapies and solutions for neurological and oncological diseases in Taiwan. The company offers LT - 1001, an analgesic injection that has completed Phase III clinical trials for severe pain relief after surgery. It is also developing LT3001, which is in Phase II clinical trial for the treatment of acute ischemic stroke; LT5001 that has completed Phase Ib clinical trial for uremic pruritus; and LT2003, which is in pre-clinical stage for the treatment of oncology. Lumosa Therapeutics Co., Ltd. was incorporated in 2000 and is based in Taipei, Taiwan.
Industry
Biotechnology
IPO Date
2015-07-16
Stock Exchange
TWO
Ticker
6535.TWO
According to Lumosa Therapeutics Co., Ltd.’s latest financial reports and current stock price. The company's current PE Ratio is -58.93. This represents a change of 344.18% compared to the average of -13.27 of the last 4 quarters.
The mean historical PE Ratio of Lumosa Therapeutics Co., Ltd. over the last ten years is -24.15. The current -58.93 PE Ratio has changed 24.30% with respect to the historical average. Over the past ten years (40 quarters), 6535.TWO's PE Ratio was at its highest in in the June 2024 quarter at 146.01. The PE Ratio was at its lowest in in the March 2025 quarter at -70.63.
Average
-24.15
Median
-16.73
Minimum
-96.22
Maximum
63.06
Discovering the peaks and valleys of Lumosa Therapeutics Co., Ltd. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 351.12%
Maximum Annual PE Ratio = 63.06
Minimum Annual Increase = -579.53%
Minimum Annual PE Ratio = -96.22
Year | PE Ratio | Change |
---|---|---|
2024 | -96.22 | 106.93% |
2023 | -46.50 | 259.47% |
2022 | -12.93 | -120.51% |
2021 | 63.06 | -579.53% |
2020 | -13.15 | -21.29% |
2019 | -16.71 | -71.89% |
2018 | -59.43 | 351.12% |
2017 | -13.17 | -21.37% |
2016 | -16.75 | -43.52% |
2015 | -29.66 | 42.36% |
The current PE Ratio of Lumosa Therapeutics Co., Ltd. (6535.TWO) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-51.88
5-year avg
-21.15
10-year avg
-24.15
Lumosa Therapeutics Co., Ltd.’s PE Ratio is
Company | PE Ratio | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Lumosa Therapeutics Co., Ltd. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Lumosa Therapeutics Co., Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Lumosa Therapeutics Co., Ltd.'s PE Ratio?
How is the PE Ratio calculated for Lumosa Therapeutics Co., Ltd. (6535.TWO)?
What is the highest PE Ratio for Lumosa Therapeutics Co., Ltd. (6535.TWO)?
What is the 3-year average PE Ratio for Lumosa Therapeutics Co., Ltd. (6535.TWO)?
What is the 5-year average PE Ratio for Lumosa Therapeutics Co., Ltd. (6535.TWO)?
How does the current PE Ratio for Lumosa Therapeutics Co., Ltd. (6535.TWO) compare to its historical average?